B. Riley analyst Mayank Mamtani initiated coverage of Denali Therapeutics with a Buy rating and $38 price target. The analyst believes Denali “stands out” within the central nervous system therapeutic space on the basis of its proprietary blood-brain barrier shuttling platform approaches. The platform enables the safe, efficient, and effective delivery of complex large and small molecules-notably antibodies, enzymes, oligos/siRNAs and protein, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics announces new interim data from Phase 1/2 study of DNL310
- Denali Therapeutics price target lowered to $31 from $37 at Wedbush
- Denali Therapeutics reports Q2 EPS $1.30 vs (48c) last year
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights